Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma

Patients with ovarian clear cell adenocarcinoma (OCCA) show a poor response to conventional platinum-based chemotherapy. Recently, it was reported that combination chemotherapy with cisplatin plus irinotecan hydrochloride (P-CPT) achieves high response rates for primary advanced and recurrent or res...

Full description

Saved in:
Bibliographic Details
Published inInternational surgery Vol. 92; no. 4; p. 202
Main Authors Takakura, Satoshi, Saito, Motoaki, Ueda, Kazu, Motegi, Makoto, Takao, Miho, Yamada, Kyosuke, Okamoto, Aikou, Niimi, Shigeki, Sasaki, Hiroshi, Tanaka, Tadao, Ochiai, Kazunori
Format Journal Article
LanguageEnglish
Published Italy 01.07.2007
Subjects
Adenocarcinoma, Clear Cell - drug therapy
Adenocarcinoma, Clear Cell - pathology
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Camptothecin - administration & dosage
Camptothecin - analogs & derivatives
Cisplatin - administration & dosage
Disease Progression
Female
Humans
Infusions, Intravenous
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Staging
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Retrospective Studies
Survival Rate
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:Patients with ovarian clear cell adenocarcinoma (OCCA) show a poor response to conventional platinum-based chemotherapy. Recently, it was reported that combination chemotherapy with cisplatin plus irinotecan hydrochloride (P-CPT) achieves high response rates for primary advanced and recurrent or resistant OCCA. We retrospectively reviewed the outcome of 20 OCCA patients treated with P-CPT by the Gynecology Service at The Jikei University Hospital after initial surgery. These patients received a total of 101 cycles of P-CPT, with a median of 5 cycles each. Two complete responses (CRs) were obtained in the three patients with measurable disease, and response duration was 7 and 15 months, respectively. One patient had stable disease (SD), and the time to progression was 5 months. The estimated 3- and 5-year survival rates were 69% and 69%, respectively. Our current data and previous reports suggest that P-CPT is a candidate first-line chemotherapy regimen for OCCA.
ISSN:0020-8868